Literature DB >> 11273721

p38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart.

A Gysembergh1, B Z Simkhovich, R A Kloner, K Przyklenk.   

Abstract

Our aim was to test the hypothesis that cardioprotection achieved with ischemic preconditioning (PC) involves increased activity of p38 mitogen-activated protein kinase (MAPK) early during sustained coronary artery occlusion. Using the isolated buffer-perfused rabbit heart model of regional ischemia, we quantified p38 MAPK activity (pmol/min/mg protein: by biochemical assay) at 5 and 10 min into coronary occlusion in hearts that first received PC ischemia or no intervention (controls), and in non-ischemic shams. Control hearts exhibited significant increases in p38 MAPK activity, averaging 883+/-142 and 1135+/-179 at 5 and 10 min of occlusion, v 144+/-49 in shams (P<0.05 and P<0.01). p38 MAPK activity was not, however, augmented with PC; rather, at 5 min into occlusion, activity was attenuated, averaging 432+/-72 (P=N.S. v sham). This early, modest reduction in p38 MAPK activity may be physiologically relevant: in additional hearts subjected to 30 min of sustained coronary occlusion and 2 h of reperfusion, infarct size (by tetrazolium staining: expressed as a % of the risk region) was 54+/-5% in hearts treated with SB 203580 (confirmed in our study to inhibit p38 MAPK activity at 5 min into occlusion) v 70+/-5% in vehicle controls (P<0.05). Thus, cardioprotection achieved with ischemic preconditioning in rabbit heart does not involve augmentation of p38 MAPK activity early during sustained coronary occlusion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273721     DOI: 10.1006/jmcc.2000.1331

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

Review 2.  Role of p38 inhibition in cardiac ischemia/reperfusion injury.

Authors:  Sarawut Kumphune; Siriporn Chattipakorn; Nipon Chattipakorn
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

Review 3.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

4.  Endocannabinoids protect the rat isolated heart against ischaemia.

Authors:  Philippe Lépicier; Jean-François Bouchard; Caroline Lagneux; Daniel Lamontagne
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

5.  Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation.

Authors:  Giuseppe Vassalli; Giuseppina Milano; Tiziano Moccetti
Journal:  J Transplant       Date:  2012-03-18

6.  Reperfusion Therapy with Rapamycin Attenuates Myocardial Infarction through Activation of AKT and ERK.

Authors:  Scott M Filippone; Arun Samidurai; Sean K Roh; Chad K Cain; Jun He; Fadi N Salloum; Rakesh C Kukreja; Anindita Das
Journal:  Oxid Med Cell Longev       Date:  2017-03-08       Impact factor: 6.543

7.  Tai Chi Improves Coronary Heart Disease Risk by Inactivating MAPK/ERK Pathway through Serum miR-126.

Authors:  Guangwei Zhang; Shuli Wang; Yan Gu; Ling Song; Shui Yu; Xiaoxing Feng
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-25       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.